Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate o...
Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and raises the price target from $6 to $8.
Guggenheim analyst Yatin Suneja upgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Buy and announces $14 price target.
Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, ...
NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstr...
JP Morgan analyst Tessa Romero downgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Underweight.
